Top executives at the largest U.S. pharmacy-benefit managers sought to defend their business practices on Capitol Hill on Tuesday, as lawmakers on both sides of the aisle excoriated the industry’s impact on the cost and accessibility of prescription drugs.
Read More: Prescription-drug middlemen face mounting bipartisan criticism on Capitol